MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 10-31-2025
Merus N.V. Book Value 2011-2026 | MRUS
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value Merus N.V.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 648 M | 356 M | 247 M | 316 M | 102 M | 131 M | 105 M | 57.5 M | 35.8 M | 30.9 M | -4.33 M | 10.6 M | 7.3 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 648 M | -4.33 M | 157 M |
Quarterly Book Value Merus N.V.
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 775 M | 842 M | 596 M | 648 M | 703 M | 747 M | 349 M | 356 M | 393 M | 257 M | 218 M | 247 M | 299 M | 327 M | 297 M | 316 M | 206 M | 219 M | 237 M | 102 M | 102 M | 102 M | 102 M | 131 M | 131 M | 131 M | 131 M | 106 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 842 M | 102 M | 324 M |
Book Value of other stocks in the Biotechnology industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aquestive Therapeutics
AQST
|
-33.7 M | $ 4.12 | -0.36 % | $ 441 M |  USA |
 |
MorphoSys AG
MOR
|
49 M | - | 2.43 % | $ 254 M |  Germany |
 |
Arcturus Therapeutics Holdings
ARCT
|
214 M | $ 8.32 | 3.67 % | $ 228 M |  Israel |
 |
Arcutis Biotherapeutics
ARQT
|
189 M | $ 23.65 | 0.08 % | $ 3.01 B | USA |
 |
BioVie
BIVI
|
19 M | $ 1.46 | 2.82 % | $ 2.16 M | USA |
 |
BioLineRx Ltd.
BLRX
|
13.5 M | $ 2.32 | 4.98 % | $ 908 M | Israel |
 |
BioNTech SE
BNTX
|
19.2 B | $ 91.44 | 0.29 % | $ 27.2 B | Germany |
 |
I-Mab
IMAB
|
5.63 B | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
253 M | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
282 M | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
34.9 M | - | -13.47 % | $ 169 M | France |
 |
BioXcel Therapeutics
BTAI
|
-95.5 M | $ 1.16 | -2.12 % | $ 14.2 M | USA |
 |
Midatech Pharma plc
MTP
|
8.32 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.33 B | - | -1.52 % | $ 24.7 M | USA |
 |
Burford Capital Limited
BUR
|
1.66 B | $ 4.52 | 9.18 % | $ 683 M | Britain |
 |
Acorda Therapeutics
ACOR
|
109 M | - | -24.86 % | $ 820 K | USA |
 |
Cabaletta Bio
CABA
|
112 M | $ 3.1 | 4.56 % | $ 311 M | USA |
 |
Adverum Biotechnologies
ADVM
|
70.7 M | - | - | $ 86.2 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
20.3 M | $ 3.17 | 1.44 % | $ 6.9 B | Israel |
 |
Advaxis
ADXS
|
16.6 M | - | -9.65 % | $ 45.9 M | USA |
 |
Applied Molecular Transport
AMTI
|
60.8 M | - | - | $ 10.1 M | USA |
 |
Aeterna Zentaris
AEZS
|
13.2 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
-37 K | - | -10.17 % | $ 12.2 K | USA |
 |
AIkido Pharma
AIKI
|
69.4 M | - | 1.93 % | $ 17.4 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
715 M | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
29.5 M | - | - | $ 26.5 M | USA |
 |
Akero Therapeutics
AKRO
|
750 M | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
234 M | - | 0.23 % | $ 488 M | USA |
 |
Catalyst Biosciences
CBIO
|
142 M | $ 19.48 | 0.39 % | $ 1.74 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
10.6 M | - | - | - |  Russia |
 |
Allena Pharmaceuticals
ALNA
|
18.9 M | - | 3.16 % | $ 1.9 M | USA |
 |
Codexis
CDXS
|
50.5 M | $ 1.95 | 6.87 % | $ 170 M | USA |
 |
Alpine Immune Sciences
ALPN
|
179 M | - | - | $ 2.17 B | USA |
 |
Aileron Therapeutics
ALRN
|
16.9 M | - | 10.36 % | $ 9.8 M | USA |
 |
Anavex Life Sciences Corp.
AVXL
|
94.9 M | $ 3.01 | 0.67 % | $ 257 M | USA |
 |
Cerus Corporation
CERS
|
65 M | $ 1.91 | 2.69 % | $ 364 M | USA |
 |
Cullinan Management
CGEM
|
409 M | $ 15.11 | 4.71 % | $ 910 M | USA |
 |
Coherus BioSciences
CHRS
|
61 M | $ 1.72 | -0.87 % | $ 201 M | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
13.5 M | $ 0.46 | -13.02 % | $ 5.27 M | Israel |
 |
Aravive
ARAV
|
10.7 M | - | -13.39 % | $ 1.45 M | USA |
 |
Aptose Biosciences
APTO
|
-27.2 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
38.3 M | - | -39.0 % | $ 4.57 M | USA |
 |
CNS Pharmaceuticals
CNSP
|
4.52 M | $ 2.25 | -0.44 % | $ 998 K | USA |
 |
CureVac N.V.
CVAC
|
688 M | - | - | $ 867 M | Germany |
 |
AstraZeneca PLC
AZN
|
48.7 B | - | - | $ 96.9 B | Britain |
 |
Catalyst Pharmaceuticals
CPRX
|
954 M | $ 24.95 | 1.05 % | $ 3.05 B | USA |
 |
Celldex Therapeutics
CLDX
|
527 M | $ 31.33 | 0.85 % | $ 2.08 B | USA |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
148 M | $ 10.27 | 0.98 % | $ 137 M | USA |
 |
Cardiff Oncology
CRDF
|
45.4 M | $ 1.6 | 1.27 % | $ 107 M | USA |
 |
Avenue Therapeutics
ATXI
|
1.83 M | - | -52.27 % | $ 4.45 M | USA |